H-100 is under clinical development by Petros Pharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect H-100’s likelihood of approval (LoA) and phase transition for Peyronies Disease took place on 18 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their H-100 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
H-100 is under development for the treatment of Peyronie's disease. The drug candidate is applied topically. It is developed based on the company's advancement in the area of sub-dermal treatment delivery.
Petros Pharmaceuticals overview
Petros Pharmaceuticals is a men’s health pharmaceutical company. The company is headquartered in Washington DC, the US.
Quick View H-100 LOA Data
|Highest Development Stage|